Recent

% | $
Quotes you view appear here for quick access.

Santarus, AŞ Message Board

  • hofno2003 hofno2003 Sep 28, 2012 2:43 AM Flag

    Ruconest PR: Pharming completes Phase III hereditary angioedema study

    Pharming had a PR concerning Ruconest US pivotal Phase III trial.

    To read the article please google with the term:
    "Pharming completes Phase III hereditary angioedema study"

    Hofno

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Important to know: Ruconest has orphan designation by FDA and an SPA. Perhaps we get a priority review and the drug is approved within 6 months from filing the NDA. This could be - IMHO - April 2013 (if filed in November).

      SNTS estimates the revenue potential to 200 mio usd, so the value of approved Ruconest for SNTS should 200mio usd / 62 mio shares = 3 usd per share x 3 (revenue multiple) = 9 usd. Thats a double from todays share price and will be gradually realised in the future.

      Hofno

      Sentiment: Strong Buy